Suvizumab

Suvizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	HIV-1
Identifiers
CAS Number	914257-21-9^N
ATC code	none
ChemSpider	none

^NY (what is this?) (verify)

Suvizumab is an antiviral and immunomodulator. It binds to HIV-1.^[1]

References

↑ "Proposed List number 102 of International Nonproprietary Names" (PDF). WHO Drug Information (Geneva: World Health Organization) 23 (4): 344. 2009. ISSN 1010-9609.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Chimeric ("-toxaxi-")	Obiltoxaximab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, April 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.